RxDoctor Payments Data

Jessica Dijulio, PA

Dermatology · Philadelphia, PANPI 1578046603

Payments from drug & device makers

$47,707in general payments, 2019–2025

Across 737 payments — averaging $64.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$29K
  • Incyte Corporation$5K
  • Verrica Pharmaceuticals Inc.$3K
  • AbbVie$2K
  • LEO Pharma Inc.$2K
  • Sanofi$1K
  • plus $5K from 24 others

What the payments were for

  • Consulting fees$6,28213%
  • Speaking & faculty fees$24,79552%
  • Travel & lodging$3,7358%
  • Food & beverage$12,19926%
  • Education$6951%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,707 in reported general payments places this provider in the 90th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$251,730
Medicare patients
813
Services billed
4,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab35$144,697
OpzeluraRuxolitinib Phosphate16$31,197
Imiquimod19$9,074
Clobetasol Propionate65$5,938
Triamcinolone Acetonide338$4,934
Ketoconazole277$4,226
Tacrolimus38$3,862
Doxycycline Hyclate142$2,236
Fluocinonide69$2,236
Clindamycin Phosphate40$1,700
Metronidazole41$1,681
Fluorouracil15$1,022
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc59$961
Mupirocin90$835
Clotrimazole38$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$4,919$31,19716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →